Watch below to learn more about the T2 Protect AD Study
Troriluzole Trial for Alzheimer's Disease
(T2 Protect AD)
T2 Protect AD is a clinical trial testing the investigational drug troriluzole in people with mild to moderate Alzheimer’s disease (AD). T2 Protect AD is taking place at dozens of sites across the United States.
The study is designed to determine if troriluzole can protect against, slow down, and potentially improve memory and thinking problems that increase as Alzheimer’s disease progresses.
More About T2 Protect AD
A potential participant goes through a screening process to determine if he/she is eligible for the T2 Protect clinical trial. Screening includes memory and thinking tests, physical examination, and EKG (heart rhythms).
Participation in the study takes 48 weeks. Study participants visit the study clinic 9 times after enrollment in the trial. At the beginning and end of the study, participants have a brain scan using magnetic resonance imaging (MRI).
Half of study participants are given the active drug and half are given an inactive pill (called a placebo) that looks exactly like the active drug.
T2 Protect AD Basic Eligibility Criteria
Women and men aged 50-85 with mild to moderate Alzheimer’s disease (otherwise, in general good health)
On stable doses of donepezil (Aricept®) or rivastigmine (Exelon®) or galantamine (Razadyne®) for at least 3 months with or without memantine (Namenda®)
Living in the community (not in a residential nursing home)
Having a study partner who has regular contact with the trial participant (about 10 hours per week). The study partner will accompany the participant to the clinic visits
Willing to participate in the T2 Study for 48 weeks
Study-related health monitoring